SLC5A2 and Hepatic fibrosis: In the meta-analysis, the SGLT-2 inhibitor group was noted to have a higher likelihood of having at least a one-score or one-stage reduction after treatment than the control group with respect to hepatocellular ballooning (RR: 2.19, 95% CI [1.22, 3.94], p = 0.009, I2 = 0%, moderate certainty of evidence) and liver fibrosis (RR: 2.29, 95% CI [1.12, 4.68], p = 0.02, I2 = 33%, moderate certainty of evidence).